+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment

Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment

Expert Opinion on Drug Metabolism and Toxicology 2019

The GEMINI trials have recently shown that a 2-drug regimen of dolutegravir plus lamivudine was non-inferior to a three-drug regimen in HIV-infected naïve patients. Accordingly, it is important that physicians be aware and confident about the drug-drug interactions (DDIs) involving dolutegravir, lamivudine and other medications. Areas covered: Here, we firstly update the available information on the pharmacokinetic features of dolutegravir and lamivudine; subsequently, the articles mainly deals with the predictable drug-drug interactions (DDIs) for both antiretroviral drugs, attempting to underline their clinical implications. This review focuses on the DDIs of dolutegravir/lamivudine combined regimen and, therefore, does not provide an exhaustive list of all the potential DDIs involving the two single agents. A MEDLINE Pubmed search for articles published from January 2000 to December 2018 was completed matching the terms dolutegravir or lamivudine with pharmacokinetics, DDIs and pharmacology. Moreover, additional studies were identified from the reference list of retrieved articles. Expert opinion: The antiretroviral dual regimen of dolutegravir and lamivudine represents an attractive therapeutic option for HIV in terms of DDIs. This is particularly relevant considering that the population with HIV is aging and is increasingly experience age-related comorbidities, increasing pill burden, polypharmacy and the risk of DDIs.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066446424

Download citation: RISBibTeXText

PMID: 30704313

DOI: 10.1080/17425255.2019.1577821

Related references

Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine. Antimicrobial Agents and ChemoTherapy 60(10): 6244-6251, 2017

Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. Journal of Medical Virology 81(1): 1-8, 2008

Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life. Current Pharmacology Reports 3(1): 1-9, 2017

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metabolism and Disposition: the Biological Fate of Chemicals 41(2): 353-361, 2013

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clinical Infectious Diseases 67(2): 193-201, 2018

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clinical Infectious Diseases 62(6): 784-791, 2016

Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. Journal of Alternative and Complementary Medicine 8(3): 293-308, 2002

Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clinical Pharmacokinetics 45(10): 1035-1050, 2006

Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Frontiers in Pharmacology 7: 175, 2016

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection. Antimicrobial Agents and ChemoTherapy 62(9), 2018

In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development. Current Topics in Medicinal Chemistry 14(11): 1325-1338, 2015

Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wiener Klinische Wochenschrift 122(3-4): 81-88, 2010

Drug-drug interactions and drug resistance will limit access to treatment in patients with HIV and hepatitis C virus coinfection. Clinical Infectious Diseases 57(1): 156-157, 2013

Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. International Journal of Clinical Pharmacology and Therapeutics 38(11): 504-513, 2000

Human liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactions. Pharmacogenomics 19(14): 1133-1138, 2018